Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Topical Drug Delivery Market
5.1. COVID-19 Landscape: Topical Drug Delivery Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Topical Drug Delivery Market, By Product
8.1. Topical Drug Delivery Market, by Product Type, 2023-2032
8.1.1. Semi-Solid Formulations
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Liquid Formulations
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Solid Formulations
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Transdermal Products
8.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Topical Drug Delivery Market, By Route of Administration
9.1. Topical Drug Delivery Market, by Route of Administration, 2023-2032
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Injectable
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Topical
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Ocular
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Pulmonary
9.1.5.1. Market Revenue and Forecast (2020-2032)
9.1.6. Implantable
9.1.6.1. Market Revenue and Forecast (2020-2032)
9.1.7. Transmucosal
9.1.7.1. Market Revenue and Forecast (2020-2032)
9.1.8. Nasal
9.1.8.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Topical Drug Delivery Market, By Application
10.1. Topical Drug Delivery Market, by Application, 2023-2032
10.1.1. Infectious Diseases
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Cancer
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Cardiovascular Diseases
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Diabetes
10.1.4.1. Market Revenue and Forecast (2020-2032)
10.1.5. Respiratory Diseases
10.1.5.1. Market Revenue and Forecast (2020-2032)
10.1.6. Others
10.1.6.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Topical Drug Delivery Market, By End User
11.1. Topical Drug Delivery Market, by End User, 2023-2032
11.1.1. Home Care Settings
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Hospitals & Clinics
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Burn Centers
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Topical Drug Delivery Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2020-2032)
12.1.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.1.3. Market Revenue and Forecast, by Application (2020-2032)
12.1.4. Market Revenue and Forecast, by End User (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.1.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.1.5.4. Market Revenue and Forecast, by End User (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.1.6.3. Market Revenue and Forecast, by Application (2020-2032)
12.1.6.4. Market Revenue and Forecast, by End User (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.2.3. Market Revenue and Forecast, by Application (2020-2032)
12.2.4. Market Revenue and Forecast, by End User (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.2.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.2.5.4. Market Revenue and Forecast, by End User (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.2.6.3. Market Revenue and Forecast, by Application (2020-2032)
12.2.6.4. Market Revenue and Forecast, by End User (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.2.7.3. Market Revenue and Forecast, by Application (2020-2032)
12.2.7.4. Market Revenue and Forecast, by End User (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.2.8.3. Market Revenue and Forecast, by Application (2020-2032)
12.2.8.4. Market Revenue and Forecast, by End User (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.3.3. Market Revenue and Forecast, by Application (2020-2032)
12.3.4. Market Revenue and Forecast, by End User (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.3.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.3.5.4. Market Revenue and Forecast, by End User (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.3.6.3. Market Revenue and Forecast, by Application (2020-2032)
12.3.6.4. Market Revenue and Forecast, by End User (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.3.7.3. Market Revenue and Forecast, by Application (2020-2032)
12.3.7.4. Market Revenue and Forecast, by End User (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.3.8.3. Market Revenue and Forecast, by Application (2020-2032)
12.3.8.4. Market Revenue and Forecast, by End User (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.4.3. Market Revenue and Forecast, by Application (2020-2032)
12.4.4. Market Revenue and Forecast, by End User (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.4.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.4.5.4. Market Revenue and Forecast, by End User (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.4.6.3. Market Revenue and Forecast, by Application (2020-2032)
12.4.6.4. Market Revenue and Forecast, by End User (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.4.7.3. Market Revenue and Forecast, by Application (2020-2032)
12.4.7.4. Market Revenue and Forecast, by End User (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.4.8.3. Market Revenue and Forecast, by Application (2020-2032)
12.4.8.4. Market Revenue and Forecast, by End User (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.5.4. Market Revenue and Forecast, by End User (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.5.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.5.5.4. Market Revenue and Forecast, by End User (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.5.6.3. Market Revenue and Forecast, by Application (2020-2032)
12.5.6.4. Market Revenue and Forecast, by End User (2020-2032)
Chapter 13. Company Profiles
13.1. Johnson & Johnson
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Novartis International AG
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. F. Hoffmann-La Roche AG
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Pfizer Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Bayer AG
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Antares Pharma, Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. GlaxoSmithKline plc
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. 3M (US), Merck & Co., Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Sanofi
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Amgen, Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client